Metabolic Dysfunction Associated Fatty Liver DiseaseNCT07285135
Dietary Glycine Supplementation in Metabolic Dysfunction-associated Steatotic Liver Disease
A study testing Glycine in people with Metabolic Dysfunction Associated Fatty Liver Disease, run by Singapore General Hospital at 1 site in Singapore.
Trial summary
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function. The study consists of two components. Read more about this study
- Who is it for?
- Ages 21 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Metabolic Dysfunction Associated Fatty Liver Disease
- What is being tested?
- Glycine
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 90 participants
- Where
- 1 siteSingapore
- Study dates
- 1 Nov 2025to Jan 2029
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- All subjects:
- Age 21-70 years
- Ability to provide informed consent.
- MASLD group:
- Hepatic steatosis on MRI
- BMI of 25-50 kg/m2
Show all 11Show fewer
- Controls:
- Absence of hepatic steatosis on MRI
- BMI of 18.5-24.9 kg/m2
- No chronic disease
- No long-term medications
Who cannot join
- Uncontrolled diabetes (HbA1c > 8%)
- Type 1 Diabetes Mellitus
- Clinically significant anemia (Haemoglobin < 10 g/dL)
- Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis
- Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
- Glomerular filtration rate (GFR < 30 ml/min)
Show all 17Show fewer
- Serum alanine transaminase (ALT) > 3x upper limit of normal (ULN)
- Serum aspartate transaminase (AST) > 3x ULN
- Liver cirrhosis
- Significant alcohol consumption (> 20g/day for women and >30g/day for men)
- Pregnancy
- Uncontrolled thyroid disease
- Previous bariatric surgery
- Weight loss > 5% in the past 1 month
- Metallic implants (including incompatible pacemakers, AICD, metallic heart valves) or other contraindications to MRI
- Claustrophobia
- Any factors likely to limit adherence to study protocol (e.g., dementia; alcohol or substance abuse; history of unreliability in medication taking or appointment keeping; significant concerns about participation in the study from spouse, significant other, or family members)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Singapore1 site, 1 recruiting
- Recruiting
Singapore General Hospital
Singapore, Singapore, 169856
Hong Chang Tan, MBBS, MMed, +65-63214658, tan.hong.chang@sgh.com.sg
Vieon Wu, 98295942, vieon.wu.aini@sgh.com.sg
About this study
Official title: Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function.
The study consists of two components. The first is a cross-sectional case-control study comparing urinary acylglycine concentrations and other glycine-dependent metabolic parameters between 60 participants with MASLD and 30 healthy controls. The second is a randomized, double-blind, placebo-controlled trial in which 60 participants with MASLD will receive either oral glycine supplementation (9 g/day) or placebo for 26 weeks.
The primary outcomes are differences in urinary acylglycine concentrations between participants with MASLD and healthy controls, and changes in hepatic fat content measured by MRI-PDFF and urinary acylglycine concentrations following supplementation. Additional assessments will evaluate amino acid metabolism, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers. Participants will undergo baseline, Week 12, and Week 26 assessments to evaluate metabolic changes and treatment responses.
Read the detailed description
This study consists of two complementary components designed to investigate abnormalities in glycine-dependent metabolic pathways in metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate the effects of dietary glycine supplementation on liver health and metabolic function.
Component 1: Cross-sectional case-control study
A total of 60 participants with MASLD and 30 healthy controls will undergo baseline clinical, imaging, and metabolic assessments. The primary objective is to compare urinary acylglycine concentrations between participants with MASLD and healthy controls to identify abnormalities in glycine conjugation metabolism. Additional metabolic profiling will characterize differences in circulating amino acids and other glycine-dependent metabolic pathways.
Healthy controls will complete their participation following the baseline assessments and will not receive dietary supplementation.
Component 2: Randomized controlled trial
The 60 participants with MASLD will be randomized in a 1:1 ratio to receive either oral glycine supplementation (9 g/day) or matching placebo for 26 weeks. The study will be double-blinded, with participants and investigators masked to treatment allocation.
The primary outcomes of the randomized trial are changes in hepatic fat content, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), and urinary acylglycine concentrations following 26 weeks of supplementation.
Additional outcomes will evaluate changes in circulating glycine and other amino acid concentrations, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers, including vitamin B12, folate, and homocysteine. These measurements will help characterize the metabolic effects of glycine supplementation and explore potential mechanisms underlying changes in liver health.
Participants will undergo baseline metabolic assessments before randomization, an interim assessment at Week 12 ± 4 weeks, and a final assessment at Week 26 ± 4 weeks. Assessments will include abdominal MRI, clinical and anthropometric measurements, blood and urine sampling, and comprehensive metabolic profiling.
Together, the two components aim to identify glycine-dependent metabolic abnormalities associated with MASLD and determine whether dietary glycine supplementation can improve hepatic steatosis and related metabolic disturbances.
- Being tested
- Glycine, Placebo
- Keywords
- Fatty liver, Randomized controlled trial, glycine supplements
- Medical subject headings
- Fatty Liver
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
GlycineDietary supplement
9g/day of glycine in capsules
PlaceboDietary supplement
Microcrystalline cellulose in identifically-looking capsules
| Study group | Role | What they receive |
|---|---|---|
| Glycine | Active comparator | 9g per day of glycine in capsules Receives: Dietary Supplement: Glycine |
| Placebo | Placebo comparator | Microcrystalline cellulose in capsules Receives: Dietary Supplement: Placebo |
| Healthy Controls | No intervention | Healthy individuals without hepatic steatosis on MRI who undergo baseline clinical, imaging and metabolic assessments. Participants complete the study after Visit 3 and receive neither glycine nor placebo. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in urinary acylglycine concentrations between MASLD participants and healthy controls
Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. The concentrations will be compared between participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and healthy controls to evaluate differences in glycine conjugation metabolism.
Measured: Baseline
Change in hepatic proton density fat fraction (MRI-PDFF) from baseline to 26 weeks
Hepatic fat content will be quantified using magnetic resonance imaging proton density fat fraction (MRI-PDFF). Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Changes in urinary acylglycine concentrations following dietary glycine supplementation.
Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine (hippurate) will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. Individual metabolite concentrations will be evaluated separately. Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Secondary outcomes (8)
Proportion achieving greater than 30% relative reduction in hepatic MRI-PDFF
The proportion of participants achieving greater than 30% relative reduction in hepatic MRI-PDFF from baseline to Week 26 will be compared between the glycine and placebo groups. Relative reduction will be calculated as [(baseline MRI-PDFF - Week 26 MRI-PDFF) / baseline MRI-PDFF] × 100.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in glutathione concentrations following dietary glycine supplementation.
Reduced glutathione (GSH), oxidized glutathione (GSSG), and/or total glutathione concentrations in mmol/L will be measured in blood-derived samples. Baseline concentrations will be compared between participants with MASLD and healthy controls. Changes from baseline to Weeks 12 and 26 will be evaluated between the glycine and placebo groups to investigate the effects of supplementation on glutathione metabolism.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in sleep quality following dietary glycine supplementation.
Sleep quality will be evaluated using the Pittsburgh Sleep Quality Index (PSQI). Changes in the PSQI global score from baseline to Weeks 12 and 26 will be compared between participants receiving glycine supplementation and placebo. Scores range from 0 to 21, with higher scores indicating poorer sleep quality.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum alanine aminotransferase (ALT) following glycine supplementation
Serum alanine aminotransferase (ALT), in U/L, will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. ALT will also be assessed at Week 12.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum alanine aspartate aminotransferase (AST) following glycine supplementation
Serum aspartate aminotransferase (AST), in U/L, will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. AST will also be assessed at Week 12.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in plasma glucose concentration following glycine supplementation
Fasting plasma glucose (mmol/L) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. Fasting serum glucose will also be assessed at Week 12.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum insulin concentration following glycine supplementation
Fasting serum insulin (U/L) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. Fasting serum insulin will also be assessed at Week 12.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in HbA1C following glycine supplementation
HbA1C (%) will be measured. Changes from screening to Week 26 will be compared between participants randomized to glycine supplementation or placebo. HbA1C will also be assessed at Week 12.
Measured: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Dec 2025
- Study start1 Nov 2025
- Primary completionJul 2028 (estimated)
- Study completionJan 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Metabolic Dysfunction Associated Fatty Liver DiseaseStudies of the same condition, open and under way.
- More trials run by Singapore General HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- This study consists of two components. The first is a cross-sectional case-control comparison involving 30 healthy controls and 60 participants with MASLD. Healthy controls undergo baseline assessments only and do not receive study intervention. The second component is a randomized, double-blind, placebo-controlled, parallel-group trial. The 60 participants with MASLD are randomized in a 1:1 ratio to receive either dietary glycine supplementation (9 g/day) or matching placebo for 26 weeks. Interim and final assessments are conducted at Weeks 12 and 26, respectively.
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 90 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Singapore General Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07285135
- Sponsor's protocol ID
- 2025-1240
- Other IDs
- CSAINV25jan-0007
- Status last verified
- Nov 2025
- First submitted
- 18 Nov 2025
- Last updated
- 27 Oct 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: All IPD that underlie results in a publication
Study at a glance
From the registry record, last updated by the sponsor on 27 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Investigating the Effects of Dietary Glycine Supplementation in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease
- ClinicalTrials.gov ID
- NCT07285135
- Acronym / sponsor ID
- 2025-1240
- Keywords
- Fatty liver, Randomized controlled trial, glycine supplements
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 90 participants (estimated)
- Lead sponsor
- Singapore General HospitalUniversity, hospital or other
- Study start
- 1 Nov 2025 (actual)
- Primary completion
- Jul 2028 (estimated)
- Study completion
- Jan 2029 (estimated)
- First posted
- 16 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to investigate abnormalities in glycine-dependent metabolic pathways in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate whether dietary glycine supplementation improves liver health and metabolic function.
The study consists of two components. The first is a cross-sectional case-control study comparing urinary acylglycine concentrations and other glycine-dependent metabolic parameters between 60 participants with MASLD and 30 healthy controls. The second is a randomized, double-blind, placebo-controlled trial in which 60 participants with MASLD will receive either oral glycine supplementation (9 g/day) or placebo for 26 weeks.
The primary outcomes are differences in urinary acylglycine concentrations between participants with MASLD and healthy controls, and changes in hepatic fat content measured by MRI-PDFF and urinary acylglycine concentrations following supplementation. Additional assessments will evaluate amino acid metabolism, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers. Participants will undergo baseline, Week 12, and Week 26 assessments to evaluate metabolic changes and treatment responses.
Detailed description
This study consists of two complementary components designed to investigate abnormalities in glycine-dependent metabolic pathways in metabolic dysfunction-associated steatotic liver disease (MASLD) and evaluate the effects of dietary glycine supplementation on liver health and metabolic function.
Component 1: Cross-sectional case-control study
A total of 60 participants with MASLD and 30 healthy controls will undergo baseline clinical, imaging, and metabolic assessments. The primary objective is to compare urinary acylglycine concentrations between participants with MASLD and healthy controls to identify abnormalities in glycine conjugation metabolism. Additional metabolic profiling will characterize differences in circulating amino acids and other glycine-dependent metabolic pathways.
Healthy controls will complete their participation following the baseline assessments and will not receive dietary supplementation.
Component 2: Randomized controlled trial
The 60 participants with MASLD will be randomized in a 1:1 ratio to receive either oral glycine supplementation (9 g/day) or matching placebo for 26 weeks. The study will be double-blinded, with participants and investigators masked to treatment allocation.
The primary outcomes of the randomized trial are changes in hepatic fat content, measured by magnetic resonance imaging proton density fat fraction (MRI-PDFF), and urinary acylglycine concentrations following 26 weeks of supplementation.
Additional outcomes will evaluate changes in circulating glycine and other amino acid concentrations, glutathione metabolism, oxidative stress, inflammatory responses, and one-carbon metabolism-related biomarkers, including vitamin B12, folate, and homocysteine. These measurements will help characterize the metabolic effects of glycine supplementation and explore potential mechanisms underlying changes in liver health.
Participants will undergo baseline metabolic assessments before randomization, an interim assessment at Week 12 ± 4 weeks, and a final assessment at Week 26 ± 4 weeks. Assessments will include abdominal MRI, clinical and anthropometric measurements, blood and urine sampling, and comprehensive metabolic profiling.
Together, the two components aim to identify glycine-dependent metabolic abnormalities associated with MASLD and determine whether dietary glycine supplementation can improve hepatic steatosis and related metabolic disturbances.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
- Model description
- This study consists of two components. The first is a cross-sectional case-control comparison involving 30 healthy controls and 60 participants with MASLD. Healthy controls undergo baseline assessments only and do not receive study intervention. The second component is a randomized, double-blind, placebo-controlled, parallel-group trial. The 60 participants with MASLD are randomized in a 1:1 ratio to receive either dietary glycine supplementation (9 g/day) or matching placebo for 26 weeks. Interim and final assessments are conducted at Weeks 12 and 26, respectively.
| Arm | Type | Receives |
|---|---|---|
| Glycine | Active comparator | Dietary Supplement: Glycine9g per day of glycine in capsules |
| Placebo | Placebo comparator | Dietary Supplement: PlaceboMicrocrystalline cellulose in capsules |
| Healthy Controls | No intervention | –Healthy individuals without hepatic steatosis on MRI who undergo baseline clinical, imaging and metabolic assessments. Participants complete the study after Visit 3 and receive neither glycine nor placebo. |
Who may qualify
- Ages
- 21 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- Age 21-70 years
- Ability to provide informed consent.
- Hepatic steatosis on MRI
- BMI of 25-50 kg/m2
- Absence of hepatic steatosis on MRI
Key exclusion criteria (17 listed)
- Uncontrolled diabetes (HbA1c > 8%)
- Type 1 Diabetes Mellitus
- Clinically significant anemia (Haemoglobin < 10 g/dL)
- Chronic liver disorders (except MASLD) such as Hepatitis B, Hepatitis C, Wilson's disease, hemochromatosis, autoimmune hepatitis, chronic cholestatic disorders, and liver cirrhosis
- Drugs that may induce hepatic steatosis, such as methotrexate, amiodarone, tamoxifen, or Systemic steroid usage (eg. prednisolone, hydrocortisone, cortisone, dexamethasone)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Glycine9g/day of glycine in capsules | Dietary supplement | Glycine |
| PlaceboMicrocrystalline cellulose in identifically-looking capsules | Dietary supplement | Placebo |
Primary outcome
Difference in urinary acylglycine concentrations between MASLD participants and healthy controls
Time frame: Baseline
Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. The concentrations will be compared between participants with metabolic dysfunction-associated steatotic liver disease (MASLD) and healthy controls to evaluate differences in glycine conjugation metabolism.
Change in hepatic proton density fat fraction (MRI-PDFF) from baseline to 26 weeks
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Hepatic fat content will be quantified using magnetic resonance imaging proton density fat fraction (MRI-PDFF). Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.
Changes in urinary acylglycine concentrations following dietary glycine supplementation.
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Urinary concentrations of acetylglycine, isobutyrylglycine, tigylglycine, isovalerylglycine, hexanoylglycine, octanoylglycine, and benzoylglycine (hippurate) will be quantified. Concentrations will be normalized to urinary creatinine and expressed as mmol/mol creatinine. Individual metabolite concentrations will be evaluated separately. Changes over time will be assessed using mixed-effects models incorporating baseline, Week 12, and Week 26 measurements. The primary comparison will be the between-group difference in change from baseline to Week 26.
8 secondary outcomes
Proportion achieving greater than 30% relative reduction in hepatic MRI-PDFF
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in glutathione concentrations following dietary glycine supplementation.
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in sleep quality following dietary glycine supplementation.
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum alanine aminotransferase (ALT) following glycine supplementation
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum alanine aspartate aminotransferase (AST) following glycine supplementation
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in plasma glucose concentration following glycine supplementation
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in serum insulin concentration following glycine supplementation
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Change in HbA1C following glycine supplementation
Time frame: Baseline, Week 12 ± 4 weeks, and Week 26 ± 4 weeks.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Oct 2026.
- Individual participant dataSharing planned: Yes. All IPD that underlie results in a publication
Related trials for Metabolic Dysfunction Associated Fatty Liver Disease
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
RecruitingPhase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NASH With Fibrosis, MASH With Fibrosis
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
RecruitingPhase 3
A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatohepatitis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Glycine in people with Metabolic Dysfunction Associated Fatty Liver Disease, run by Singapore General Hospital at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hong Chang Tan, MD PhD (+65 63214658, tan.hong.chang@singhealth.com.sg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in urinary acylglycine concentrations between MASLD participants and healthy controls (time frame: Baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Oct 2026.